特比萘芬治疗念珠菌性阴道炎100例疗效观察

为观察特比萘芬治疗念珠菌性阴道炎疗效，选择念珠菌性阴道炎患者100例，口服特比萘芬250mg, 每日1次，连服2周，停药时及停药后4周、8周复诊，观察疗效。治疗前后作真菌镜检及培养，鉴定菌种，观察真菌清除率，并作抑菌实验，测定MIC值。结果口服特比萘芬治疗念珠菌性阴道炎，治愈率85％，总有效率达93％。口服特比萘芬治疗念珠菌性阴道炎疗效良好。     

特比萘芬与伊曲康唑序贯疗法治疗复发性念珠菌性阴道炎疗效观察

为探索复发性念珠菌性阴道炎更有效治疗方法,按就诊次序收集病例,随机分为治疗组、对照1组、对照2组.治疗组给予特比萘芬250 mg每日1次口服,连服7天,接着给予伊曲康唑200 mg每日1次口服,连服7天.对照1组给予特比萘芬250 mg每日1次口服,连服14天.对照2组给予伊曲康唑200 mg每日1次口服,连服14天.结果:治疗结束后第8周和第12周,治疗组的有效率和复发率显著优于对照1组、对照2组.特比萘芬与伊曲康唑序贯疗法治疗复发性念珠菌性阴道炎疗效高,复发率低.     

特比萘芬治疗外阴阴道念珠菌病的疗效观察

目的观察特比萘芬与伊曲康唑治疗外阴阴道假丝酵母菌病(念珠菌性外阴阴道炎)的疗效。方法选择本院妇科门诊诊断为外阴阴道假丝酵母菌病患者120例,随机分为治疗组和对照组各60例,分别予口服特比萘芬250mg、伊曲康唑200mg均1次/d,连服2周。结果治疗组和对照组有效率分别为81.7%和83.3%,差异无显著性(P=0.901);两组不良反应发生率差异亦无显著性(P>0.05)。结论口服特比萘芬治疗外阴阴道假丝酵母菌病疗效良好,不良反应少。     

特比萘芬治疗念珠菌性外阴阴道炎、龟头炎临床观察

为观察特比萘芬治疗念珠菌性外阴道炎、龟头炎的疗效及不良反应，采用特比萘芬0.25g，日1次，连服1周对23例包皮龟头炎、37例外阴阴道炎患者进行了治疗。结果：停药1周后，外阴阴道炎的有效率为97.30%，包皮龟头炎的有效率为100%；真菌清除率达96.67%。结果口服特比萘芬治疗念珠菌性外阴阴道炎、包皮龟头炎疗效显著。     

盐酸特比萘芬治疗念珠菌性包皮龟头炎疗效观察

目的：观察盐酸特比萘芬对念珠菌性包皮龟头炎（CBP）的疗效。方法：48例患者分两组，分别口服特比萘芬与伊曲康唑，根据真菌培养判定疗效。结果：治疗组痊愈率86．4％，对照组痊愈率80．8％，P＞0．05。结论：特比萘芬对CBP有较好疗效。     

伊曲康唑与特比萘芬治疗念珠菌性慢性前列腺炎附睾炎的疗效观察

目的 对性病治疗后有慢性前列腺炎附睾炎的673例患者做精液或前列腺液的真菌培养，发现45例念珠菌感染，占6．69％，给予伊曲康唑及特比萘芬治疗并进行临床观察。方法 采用科玛嘉定位显色真菌培养，对念珠菌阳性患者随机分为2组，1组口服伊曲康唑200mg，每日1次，连服14d，2组口服特比萘芬250mg，每日1次，连服14d。结果 45例念珠菌阳性者中，光滑念珠菌2l例，白念珠菌16例，热带念珠菌5例，克柔念珠菌3例。随机分组治疗后，1组临床总有效率为82．6l％，2组临床总有效率为86．36％，1组真菌学治愈率为78．26％，2组真菌学治愈率为72．73％，两组临床有效率及真菌学治愈率经卡方检验差异无显著性。结论 念珠菌是性病治疗后慢性前列腺炎附睾炎的致病原因之一，伊曲康唑和特比萘芬可作为治疗念珠菌性慢性前列腺炎附睾炎的有效和安全药物。     

国产伊曲康唑治疗皮肤浅部真菌病216例疗效观察

为观察国产伊曲康唑（美扶）治疗浅部真菌病的疗效。选择216例皮肤浅部真菌病患者，均口服美扶治疗，其中手足癣组口服美扶200mg，bid，连服7天；其余各组口服美扶200mg，qd，连服7天。停药3周评价疗效。结果：手足癣、体股癣、花斑癣、马拉色菌毛囊炎、念珠菌性包皮龟头炎和念珠菌性阴道炎总有效率分别为94．12％、97．47％、95．65％、81．25％、100％、81．25％。国产伊曲康唑治疗浅部真菌病疗效好、经济而安全。     

特比萘芬治疗念珠菌性外阴阴道炎疗效和安全性评价

目的观察特比萘芬治疗念珠菌性外阴阴道炎的疗效及安全性。方法选择本院念珠菌性外阴阴道炎患者,随机分为治疗组34例,口服特比萘芬250mg,1次/d;对照组31例,口服伊曲康唑200mg,1次/d。两组均连用10天。结果治疗组和对照组有效率分别为67.65%和87.10%,真菌清除率分别为82.35%和83.87%,两组有效率和真菌清除率比较差异均无显著性意义(P均>0.05)。结论口服特比萘芬治疗念珠菌性外阴阴道炎疗效肯定,安全性高。     

伊曲康唑与特比萘芬治疗儿童头癣疗效观察

目的:寻找治疗儿童头癣有效、安全的方法。方法:应用伊曲康唑治疗儿童头癣27例,特比萘芬治疗儿童头癣25例,并作疗效与真菌清除率观察。结果两种药物在用药8周以上的总有效率无明显差异,但伊曲康唑于用药第4周与第6周时疗效存在显著性差异,而特比萘芬在用药第6周与第8周时疗效存在显著性差异。结论:伊曲康唑与特比萘芬对治疗儿童头癣都是有效安全的,但伊曲康唑疗程需达6周,而特比萘芬疗程需达8周;伊曲康唑6周时达到真菌清除;而特比萘芬需达8周。     

口服特比萘芬治疗外阴阴道念珠菌病疗效观察

目的：观察特比萘芬治疗外阴阴道念珠菌病的临床及真菌学疗效。方法：选择外阴阴道念珠菌病患者150例，口服特比萘芬250mg，每日1次，连续口服2周，停药时及停药后4周、8周复诊，观察疗效。治疗前后作真菌镜检及培养，鉴定菌种，观察真菌清除率，并作抑菌试验，测定MIC值。结果：口服特比萘芬治疗外阴阴道念珠菌病，总有效率及真菌清除率均达到94％。结论：口服特比萘芬治疗外阴阴道念珠菌病，方法简单、疗效高。     

皮肤癣菌感染动物模型的建立及抗真菌治疗的评价

目的 建立皮肤癣菌感染动物模型并评价抗真菌药物对该模型的体内疗效。方法 选择38只健康豚鼠,随机分为须癣毛癣菌感染组和犬小孢子菌感染组,用磨砂法建立皮肤癣菌感染的动物模型,每组各有1只为阴性对照。每组18只感染动物再随机分为伊曲康唑治疗组、特比萘芬治疗组、未治疗组3个组。在治疗后的第8、11、14天分别对动物模型进行皮肤病变评分和真菌学检查。结果 未进行治疗的感染动物均出现明显的皮损,且真菌学检查为阳性。须癣毛癣菌感染的伊曲康唑治疗组动物皮损评分和真菌学治愈率在第8、11、14天分别为9、1、0,66.7%、83.3%、83.3%;特比萘芬治疗组分别为8、5、1,83.3%、83.3%、83.3%;未治疗组分别为48、52、40,0%、0%、0%。犬小孢子菌感染的伊曲康唑治疗组动物皮损评分和真菌学治愈率在第8、11、14天分别为3、0、0,83.3%、83.3%、83.3%,特比萘芬治疗组分别为9、2、0,83.3%、83.3%、83.3%,未治疗组分别为46、47、39,0%、0%、0%。两组与未治疗组比较,差异均有统计学意义（P < 0.01）,但伊曲康唑治疗组与特比萘芬治疗组比较差异无统计学意义（P > 0.05）。结论 伊曲康唑治疗须癣毛癣菌和犬小孢子菌感染的动物模型有良好的疗效,特比萘芬有相似的结果。     

An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis

BACKGROUND: Onychomycosis is a recalcitrant disease of the nails caused by dermatophytes, yeasts, and molds. AIMS: To compare the clinical efficacy of oral itraconazole pulse therapy and oral terbinafine pulse therapy in onychomycosis. METHODS: A randomized single-blind clinical comparative study was undertaken on 120 patients of onychomycosis during the period March 1999-February 2002. Sixty patients were randomly assigned to receive oral itraconazole 100 mg, two capsules twice daily for seven days a month and the other group of sixty patients received oral terbinafine 250 mg, one tablet twice daily for seven days every month. Four such monthly pulses were administered for each drug. The patients were evaluated at 4-weekly intervals till sixteen weeks and then at 24, 36 and 48 weeks. RESULTS: We observed a clinical cure rate of 82% and mycological cure rate of 90% in the group of patients treated with itraconazole while the group with terbinafine showed clinical and mycological cure rates of 79% and 87% respectively. This difference was not statistically significant. CONCLUSIONS: Both oral itraconazole and terbinafine are effective in the treatment of onychomycosis when administered in the pulse dosage form. Terbinafine is more cost effective while itraconazole has a broader spectrum of antimycotic activity.     

Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly

BACKGROUND: The 2 most common agents used to treat dermatophyte onychomycosis of the toe are terbinafine (continuous) and itraconazole (pulse). Although comparative studies have been performed evaluating the efficacy of these 2 agents in adults, no such studies have been reported specifically in the elderly subset. OBJECTIVE: This prospective, randomized, single-blind, non--industry-sponsored, comparative study evaluated the efficacy and safety of terbinafine (continuous) and itraconazole (pulse) therapies in the treatment of dermatophyte onychomycosis of the toe in the elderly population. METHODS: Elderly patients (> or =60 years old) with dermatophyte onychomycosis of at least 1 great toe were randomly assigned to receive either terbinafine 250 mg/day for 12 weeks or itraconazole (pulse) 200 mg twice a day for 1 week, given for 3 pulses. At month 6 from the start of therapy, if there was less than 50% reduction in the affected nail plate area compared with baseline, or if there was less than 3 mm outgrowth of unaffected nail plate as measured in midline, then patients who had been administered terbinafine (continuous) therapy were given an extra 4 weeks of the drug (total of 16 weeks of therapy), and those who had received itraconazole (pulse) therapy were given an extra pulse (fourth pulse). Patients were evaluated at 1.5, 3, 6, 12, and 18 months from the start of therapy. The efficacy measures included mycologic cure rate and clinical efficacy (mycologic cure plus clinical cure or clinical improvement so that 10% or less of nail plate was clinically involved). RESULTS: There were 101 elderly patients enrolled in the study with 50 and 51 patients receiving terbinafine and itraconazole, respectively. The terbinafine group consisted of 28 men and 22 women, age (mean +/- standard error [SE]) 68.0 +/- 0.9 years, duration of onychomycosis (mean +/- SE) 18.2 +/- 1.4 years, number of nails involved (mean +/- SE) 5.5 +/- 0.5, and percent baseline nail plate area involved (mean +/- SE) 67.5% +/- 4.2%. The corresponding figures for the itraconazole (pulse) group were 24 men and 27 women, age (mean +/- SE) 68.8 +/- 0.8 years, duration of onychomycosis (mean +/- SE) 16.1 +/- 1.7 years, number of nails involved (mean +/- SE) 6.0 +/- 0.7, and percent baseline nail plate area involved (mean +/- SE) 74.9% +/- 3.8%, respectively, with no significant difference between the groups. At month 6, the number of patients that required an extra 4 weeks of terbinafine in the allylamine group or an extra itraconazole pulse in the triazole group was 13 of 50 and 23 of 51, respectively. The mycologic cure rate and clinical efficacy at 18 months from the start of therapy for the terbinafine group were 64.0% and 62.0%, respectively. The corresponding figures for the itraconazole (pulse) group were 62.7% and 60.8%, respectively, with no significant difference between the 2 groups. There were no dropouts during therapy. For both groups the drug appeared safe with no significant adverse events (AEs) or clinically significant laboratory abnormalities. All the AEs were mild and transient. There was high compliance with both regimens. CONCLUSIONS: In the elderly, for the treatment of dermatophyte toe onychomycosis, both terbinafine (continuous) and itraconazole (pulse) therapies are effective, safe, and associated with high compliance.     

Metronidazole in the treatment of non-specific vaginitis (NSV).

In a large multicentre study of 429 patients with the usual signs and symptoms of non-specific vaginitis (NSV), we studied the effect of different doses of metronidazole. The patients were divided into five treatment groups as follows: group A was given 400 mg metronidazole three times daily for seven days, group B 2000 mg as a single dose, group C 2000 mg on days 1 and 2, group D 2000 mg on days 1 and 3, and group E was given 1200 mg metronidazole once daily for five days. At follow up examination four weeks from the start of treatment, patients in groups D and E showed the best clinical results with cure rates of 94.0% and 93.6% respectively. In addition the rate of reisolation of Gardnerella vaginalis was lowest in group D. We therefore recommend metronidazole 2000 mg on days 1 and 3 as routine treatment for non-specific or vaginitis associated with gardnerella.     

口服特比萘芬与伊曲康唑治疗儿童头癣的疗效比较

目的比较口服特比萘芬与伊曲康唑治疗儿童头癣的疗效。方法 2021年1-12月北京儿童医院皮肤科门诊头癣患儿53例, 采用随机数字表法分为特比萘芬治疗组(体重< 20 kg, 剂量62.5 mg/d;体重20 ～ 40 kg, 剂量125 mg/d;体重> 40 kg, 剂量250 mg/d)和伊曲康唑治疗组(3 ～ 5 mg·kg-1·d-1)。使用SPSS23.0软件进行统计分析, 组间计数资料比较采用χ2检验或Fisher确切概率法。结果特比萘芬治疗组27例(白癣17例、脓癣10例), 治愈14例(51.85%), 其中白癣5例, 脓癣9例。伊曲康唑治疗组26例(白癣17例、脓癣9例), 治愈25例(96.15%), 其中白癣16例, 脓癣9例。伊曲康唑组的疗效显著高于特比萘芬组, χ2 = 13.37, P < 0.001。结论伊曲康唑治疗儿童白癣的效果优于特比萘芬, 但两药治疗儿童脓癣的疗效相当。     

特比萘芬联合黄蒲洁夫洗剂治疗念珠菌性龟头炎疗效观察

目的:观察特比萘芬联合黄蒲洁夫洗剂治疗念珠茵性龟头炎的疗效.方法:选择100例念珠茵性龟头炎患者随机分成两组,治疗组50例,采用特比萘芬250mg/次,1次/d,联合黄蒲洁夫洗剂外洗,2次/d;对照组50例单纯使用特比萘芬250mg/次,次/d,2周后根据临床症状、体征及真茵学镜检判定治疗.结果:治疗组临床疗效、真菌学疗效明显优于对照组,差异有显著性(P＜0.05).治疗组复发率明显低于对照组.结论:特比萘芬联合黄蒲洁夫洗剂治疗念珠茵性龟头炎疗效明显,复发率低,副作用小,为临床治疗念珠茵性龟头炎提供一种治疗手段.     

Itraconazole and Terbinafine Treatment of Some Nondermatophyte Molds Causing Onychomycosis of the Toes and a Review of the Literature

BACKGROUND: Onychomycosis may be caused by dermatophytes (which form the majority of organisms), Candida species, and nondermatophyte molds. OBJECTIVE: To evaluate the efficacy and safety of itraconazole and terbinafine in the treatment of some nondermatophyte molds that cause toe onychomycosis and to review the literature on the treatment of nondermatophyte mold toe onychomycosis using the oral antifungal agents. PATIENTS AND METHODS: Patients with nondermatophyte mold toe onychomycosis were treated in an open, prospective manner with either itraconazole (pulse) or terbinafine therapy. In each instance, light microscopic examination was consistent with the diagnosis of a nondermatophyte mold. For each patient, mycological evaluation of the target nail resulted in 3 or more successive cultures yielding growth of the mold alone. RESULTS: All 15 patients had onychomycosis of the toes which was of the distal and lateral type. The patients were treated with itraconazole given as the standard 3 pulses with additional pulses administered depending upon the response exhibited by the toe onychomycosis in the patient. Similarly, terbinafine was given for 12 weeks with additional therapy administered as dictated by the response. Efficacy parameters were mycological cure (MC) and clinical cure (CC). Mycological cure was negative light microscopic examination (KOH) and culture. Clinical cure was the appearance of a completely normal-looking nail. At month 12 from the start of treatment, the response was as follows: Scopulariopsis brevicaulis: itraconazole (MC 4/4, CC 2/4) and terbinafine (MC 0/1, CC 0/1), Fusarium species: itraconazole (MC 1/1, CC 1/1) and terbinafine (MC 0/1, CC 0/1), Aspergillus species: itraconazole (MC 5/6, CC 3/6), Alternaria alternata: itraconazole (MC 0/1,CC 0/1), and Onychocola canadensis: itraconazole (MC 1/1, CC 0/1). There were no significant clinical or laboratory adverse effects. CONCLUSIONS: In the present series itraconazole demonstrated efficacy against onychomycosis of the toenails caused by S. brevicaulis and Aspergillus species. A review of the literature confirms our experience with itraconazole and further suggests that terbinafine may also demonstrate efficacy against cases of S. brevicaulis and Aspergillus toe onychomycosis. Additionally, reports in the literature suggest that pedal onychomycosis caused by Fusarium species may also show response to itraconazole and terbinafine. For the other species, there are fewer data, making it difficult to draw conclusions.     

四种抗真菌药物治疗甲癣疗效比较的文献系统复习

目的比较特比萘芬与伊曲康唑、氟康唑、灰黄霉素治疗甲癣疗效的差异。方法检索Medline文献数据库,查找所有比较特比萘芬与伊曲康唑、氟康唑、灰黄霉素治疗甲癣的双盲随机对照试验的文献,找出这4种药物治疗甲癣的真菌学治愈率并对其进行汇总,得出合并后真菌学治愈率的比值比(OR)及其95%可信区间(CI)。结果①有6篇比较特比萘芬与伊曲康唑、1篇特比萘芬与氟康唑、2篇特比萘芬与灰黄霉素治疗甲癣的双盲随机对照试验文献被纳入。②特比萘芬250mg/d连续疗法优于伊曲康唑400mg/d冲击疗法[OR=5.01,95%CI(3.42～7.33)]和伊曲康唑200mg/d连续疗法[OR=2.58,95%CI(1.91～3.49)]。特比萘芬的疗效亦优于氟康唑(P<0.001)和灰黄霉素[OR=3.46,95%CI(1.89～6.31)]。结论特比萘芬治疗甲癣的疗效优于伊曲康唑、氟康唑和灰黄霉素。     

Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus

BACKGROUND: Oral terbinafine and oral itraconazole are two of the most common agents used for the treatment of toenail dermatophyte onychomycosis. Despite the fact that diabetic patients are more likely to have onychomycosis than normal individuals are, there is little research into the efficacy of standard oral regimens of terbinafine and itraconazole for onychomycosis in the diabetic population. STUDY DESIGN: We present a prospective, randomized, single-blind, parallel group, comparator-controlled, multi-centre study designed to assess the efficacy of the pulse itraconazole (200 mg twice daily, 1 week on, 3 weeks off, for 12 weeks) vs. continuous terbinafine (250 mg once daily for 12 weeks) oral therapies in the treatment of dermatophyte toenail distal and lateral subungual onychomycosis (DLSO) in the diabetic population. EFFICACY PARAMETERS: Primary efficacy measures included mycological cure rate (negative KOH and culture) and effective cure (mycological cure plus nail plate involvement of 10% or less) at Week 48. RESULTS: At Week 48, mycological cure was attained by 88.2% (30 of 34) and 79.3% (23 of 29) of patients in the itraconazole and terbinafine groups, respectively (P not significant). Effective cure (mycological cure with 相似文献